• English
  • Français
Bladder Cancer CanadaBladder Cancer CanadaBladder Cancer CanadaBladder Cancer Canada
  • Bladder Cancer
    • See Red?
    • What is Bladder Cancer?
    • Statistics and Risk Factors
    • Symptoms and Diagnosis
    • Staging and Grading
    • Types of Bladder Cancer
      • Non-Muscle Invasive Bladder Cancer
      • Muscle Invasive Bladder Cancer
      • Metastatic Bladder Cancer
      • Upper Tract Urothelial Carcinoma
    • Treatment Options
      • TURBT
      • BCG
      • Chemotherapy and Radiation
      • Bladder Removal Surgery
      • Immunotherapy
      • Bladder Preservation Options
      • Palliative Care
      • Clinical Trials
      • Advanced Bladder Cancer Treatment
    • Research and Studies
  • Patients
    • Get Support
      • Support Groups
      • One2One Peer Support
      • Online Discussion Forum
      • Contact Us by Phone or Email
    • Navigating Your Diagnosis
      • Newly Diagnosed?
      • Coping With Emotions
      • Health and Wellness Resources
      • Clinical Trials
    • Educational Resources
      • Guidebooks
      • Webinars and Videos
      • Podcast
      • Newsletter
      • Glossary
    • Upcoming Events
    • News and Stories
    • Links and Other Resources
  • Get Involved
    • Donate
    • Fundraise
    • Volunteer
    • Share Your Story
    • Patient Study Recruitment
    • Patient Self-Advocacy
    • Bladder Cancer Awareness Month
    • Your Impact
  • Health Care Practitioners
    • Doctor Resources
    • BCC Research Grant Applications
    • BCC Research Grant Recipients
    • CBCIS
    • CBCRN
    • Medical Advisory Board
  • About Us
    • Who We Are
    • Board of Directors
    • Staff
    • Medical Advisory Board
    • Sponsors and Partners
    • Financial Statements and Annual Reports
    • Newsletter
    • Contact Us
  • Walk With Us
  • Donate
NextPrevious

Health Canada releases VERITY-BCG™ bladder cancer treatment for distribution

By Bladder Cancer Canada | Latest news and stories | 9 September, 2021 | 2

Critical Bladder Cancer Drug Now Fully Available After Years of Shortages

Health Canada releases VERITY-BCG™ bladder cancer treatment for distribution

From Verity Pharmaceuticals:

TORONTO, Sept. 9, 2021 /CNW/ – Verity Pharmaceuticals Inc. is pleased to announce that it has received approval to begin distributing VERITY-BCG™ (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I). This approval means that hospitals and clinics across Canada will no longer see shortages of this critical drug. 

“Our patient community has faced the stress of realizing that there has been a shortage of BCG, which has resulted in a drug rationing approach at many institutions across Canada,” said Ferg Devins, Survivor and Volunteer Chair of Bladder Cancer Canada. “This announcement is truly a relief for all of us who have faced uncertainty resulting from this long term shortage. We are delighted that Health Canada has finally approved another supplier of BCG in Canada.  It will greatly improve patient care,” added Devins.

Bacillus Calmette-Guérin (BCG) is a proven immunotherapy of choice for bladder cancer. It is used as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. Several large pharmaceutical manufacturers of BCG announced shortages within the last decade or stopped production altogether, leading to a worldwide scarcity of the treatment. Verity partnered with Serum Institute of India, which manufactures BCG. Serum Institute is the world’s largest manufacturer of vaccines.  

“Increasing global usage and demand of BCG has resulted in a limited and erratic supply for decades and Canada has had just one supplier since 2016,” said Howard Glase, Chief Executive Officer, Verity Pharma. “With the addition of VERITY-BCG to the Canadian healthcare system, Canada becomes the first country in the western world to solve the BCG shortage crisis. VERITY-BCG is an example of our expertise in supplying life-saving therapeutic options to help fulfill unmet patient needs.” 

Bladder Cancer Canada states that bladder cancer is the fifth most common cancer in Canada and that almost 12,000 people will be diagnosed with bladder cancer this year alone.

“BCG is a proven and effective adjunct to transurethral resection (TUR) and the gold standard of care,” said Dr. Alexandre Zlotta, Department of Surgery, Division of Urology, University of Toronto. “It is used to help keep the cancer from coming back and potentially becoming life-threatening. It is also the best known immuno-oncological agent, used the last three decades. However, in the last years, BCG shortages were leading to rationing and dose reduction of this crucial bladder cancer drug with unfortunate impact on outcomes. Patients had delayed or sometimes even cancelled treatments. With the availability of VERITY-BCG, Canada’s multi-year BCG drug shortage will be a thing of the past as Canadian patients will now have full access to this well-established, safe and efficacious therapy. It will also foster further scientific studies and research.”

Amit Thatte, Director of Serum Institute Inc, said the facility supplies BCG for bladder cancer instillations to more than 21 countries around the world.

 “As the manufacturer of the product, we are very pleased to partner with Verity Pharma for the approval and supply of Verity BCG to Canada.” he said. “Serum Institute is the world’s largest vaccine manufacturer by number of doses produced and sold globally and we take great pride in delivering a safe, efficacious, high-quality product to all of our partners. Our world-class research and production facilities are continuously upgraded to ensure compliance with all regulations and have been accredited by the World Health Organization. We are very happy to have our partnership with Verity Pharma and look forward to providing this life-saving therapy to Canada for years to come.”

Ajay Bisaria, High Commissioner of India to Canada, welcomed the announcement. 

“India is proud to support this effort to resolve the shortage of BCG in Canada,” he said. “With more than 60 percent of global vaccine manufacturing capacity, India believes in vaccine internationalism. This collaboration between the Serum Institute of India and Verity Pharma is a clear demonstration of our commitment to global health.”

About VERITY-BCG™

VERITY-BCG™ is an adjuvant therapy after transurethral resection (TUR) of a primary or relapsing superficial papillary urothelial cell carcinoma of the bladder stage Ta (grade 2 or 3) or T1 (grade 1, 2, or 3), without concomitant carcinoma in situ.  It is only recommended for stage Ta grade 1 papillary tumors, when there is judged to be a high risk (>50%) of tumor recurrence.

More information is available here: https://veritypharma.com/products/

Contact information for HCP questions:

Email: medinfo@veritypharma.com 
Phone: 1-800-977-9778

About Verity Pharmaceuticals Inc.

Founded in Canada and owned by Canadians, and with a head office in Mississauga, Ontario, Verity Pharmaceuticals is a specialty pharmaceutical company focused on providing therapeutically relevant agents to the Canadian healthcare community. Our mission is to provide access to prescription products that are in short supply or have not yet been made available in Canada. 

Verity Pharmaceuticals works with best-in-class global pharmaceutical manufacturing partners to ensure that product quality and availability is a constant deliverable. We are also committed to supporting programs, initiatives and organizations that help improve health, expand research opportunities, and promote education within the Canadian healthcare community.

No tags.

Related Post

  • Volunteer’s personal approach leads to deeper commitment from corporate supporter

    By Bladder Cancer Canada | 0 comment

    By: Tom Eremondi Read time: 3.5 minutes Admittedly old school, Gerry Ross’ approach to dealing with a local walk sponsor nurtured and enhanced the relationship to a surprising level. This story, however, dates back aboutRead more

  • “The risk of recurrence of my cancer is high, so I need to take care of myself.”

    By Bladder Cancer Canada | 0 comment

    Read time: 2 minutes We were so pleased to see one of our new Peer Support Volunteers, Gervais  Fournier, featured in this New Normal, Same Cancer news story, seen last month in the Le JournalRead more

  • This May, we’re making bladder cancer impossible to ignore! 

    By Bladder Cancer Canada | Comments are Closed

    Subscribe today! Our May newsletter is filled with lots of initiatives to create awareness for bladder cancer including blogs, podcasts, helpful facts, webinars and more. Bladder cancer is the 5th most common cancer in Canada andRead more

  • Bladder cancer & COVID-19 FAQ

    By Bladder Cancer Canada | Comments are Closed

    Uncertain times are upon us, around the world, as we globally respond to the coronavirus (COVID-19) that is affecting us all on some level. Many members of our bladder cancer community are directing questions our way aboutRead more

  • Protecting Yourself During the Coronavirus Outbreak

    By Bladder Cancer Canada | Comments are Closed

    (The following content is sourced from various sites advising on the coronavirus. For more information, please see the end of this article for additional resources. Photo Credit: CDC) As news of the coronavirus (COVID-19) continues toRead more

  • Health Canada Approves BALVERSA

    By Bladder Cancer Canada | Comments are Closed

    In a recent press release, Janssen Pharmaceutical Companies of Johnson & Johnson have announced that they have received approval from Health Canada for BALVERSA™ (erdafitinib), the first FGFR Kinase inhibitor for the treatment of patientsRead more

  • Patient Story: Ann

    By Bladder Cancer Canada | Comments are Closed

    I was diagnosed with bladder cancer after a significant amount of blood appeared in my urine.

  • Announcing the Launch of Our New Hematuria Brochure: A Vital Resource for Early Bladder Cancer Detection 

    By Bladder Cancer Canada | Comments are Closed

    We have developed this easy-to-understand resource aimed at increasing awareness of hematuria.

  • Our First Annual Research Report Is Live! 

    By Bladder Cancer Canada | Comments are Closed

    Our first Annual Research Report brings you exciting updates from the world of bladder cancer research.

  • Tax Season is Upon Us! 

    By Bladder Cancer Canada | Comments are Closed

    Spring has sprung and so has tax season! Don’t miss out on valuable credits or deductions! 

  • Happy National Volunteer Week 2025!

    By Bladder Cancer Canada | Comments are Closed

    National Volunteer Week is celebrated annually to honour all the volunteers who make a powerful impact.

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

NextPrevious

Recent Blog Posts

  • Patient Story: Ann
  • Announcing the Launch of Our New Hematuria Brochure: A Vital Resource for Early Bladder Cancer Detection 
  • Our First Annual Research Report Is Live! 
  • Economic Impacts of a Cancer Diagnosis on Canadians
  • Tax Season is Upon Us! 

Upcoming Events

  • Outreach Events
  • In-person Education Events
  • Support Groups
  • Webinars

Blog Categories

  • Blog
  • Honouring our volunteers
  • Latest news and stories
  • Patient Stories
  • Upcoming meeting and events
  • Volunteers
  • Webinar

Bladder Cancer Canada

4936 Yonge Street, Suite 1000, Toronto, ON M2N 6S3
Phone: 1-866-674-8889
Email & Media Contact: info@bladdercancercanada.org

Privacy Policy | Donor Bill of Rights

Charitable Reg No. 83612 6060 RR0001

© Bladder Cancer Canada.

SUBSCRIBE TO OUR NEWSLETTER
SEND US A MESSAGE
  • Bladder Cancer
    • See Red?
    • What is Bladder Cancer?
    • Statistics and Risk Factors
    • Symptoms and Diagnosis
    • Staging and Grading
    • Types of Bladder Cancer
      • Non-Muscle Invasive Bladder Cancer
      • Muscle Invasive Bladder Cancer
      • Metastatic Bladder Cancer
      • Upper Tract Urothelial Carcinoma
    • Treatment Options
      • TURBT
      • BCG
      • Chemotherapy and Radiation
      • Bladder Removal Surgery
      • Immunotherapy
      • Bladder Preservation Options
      • Palliative Care
      • Clinical Trials
      • Advanced Bladder Cancer Treatment
    • Research and Studies
  • Patients
    • Get Support
      • Support Groups
      • One2One Peer Support
      • Online Discussion Forum
      • Contact Us by Phone or Email
    • Navigating Your Diagnosis
      • Newly Diagnosed?
      • Coping With Emotions
      • Health and Wellness Resources
      • Clinical Trials
    • Educational Resources
      • Guidebooks
      • Webinars and Videos
      • Podcast
      • Newsletter
      • Glossary
    • Upcoming Events
    • News and Stories
    • Links and Other Resources
  • Get Involved
    • Donate
    • Fundraise
    • Volunteer
    • Share Your Story
    • Patient Study Recruitment
    • Patient Self-Advocacy
    • Bladder Cancer Awareness Month
    • Your Impact
  • Health Care Practitioners
    • Doctor Resources
    • BCC Research Grant Applications
    • BCC Research Grant Recipients
    • CBCIS
    • CBCRN
    • Medical Advisory Board
  • About Us
    • Who We Are
    • Board of Directors
    • Staff
    • Medical Advisory Board
    • Sponsors and Partners
    • Financial Statements and Annual Reports
    • Newsletter
    • Contact Us
  • Walk With Us
  • Donate
Bladder Cancer Canada